Trazodone 100 mg for Insomnia: Can It Cause Hyponatremia?
Yes, trazodone 100 mg prescribed for insomnia can definitely cause hyponatremia, and this risk is explicitly warned about in the FDA drug label.
Direct FDA Warning
The FDA label for trazodone clearly states that hyponatremia may occur as a result of treatment with trazodone, with documented cases showing serum sodium levels dropping below 110 mmol/L 1. This hyponatremia frequently results from syndrome of inappropriate antidiuretic hormone secretion (SIADH) and can manifest with serious consequences including:
- Headache, confusion, memory impairment, and weakness
- Falls due to unsteadiness
- In severe cases: hallucinations, syncope, seizures, coma, respiratory arrest, and death 1
High-Risk Populations Requiring Extra Vigilance
Elderly patients, those taking diuretics, and volume-depleted individuals face substantially elevated risk 1. The 2019 American Geriatrics Society Beers Criteria specifically notes that tramadol (a related serotonergic agent) was added to the list of drugs associated with hyponatremia/SIADH, highlighting the broader concern with serotonergic medications in older adults 2.
Clinical Evidence Supporting This Risk
A fatal case report documented a 37-year-old woman who developed severe hyponatremia from SIADH after trazodone overdose, progressing to seizures and fatal cerebral edema 3. While this was an overdose scenario, it demonstrates trazodone's clear mechanistic link to hyponatremia.
Research data shows that serotonergic antidepressants (including trazodone) carry hyponatremia risk, with the highest incidence occurring during the first few weeks of treatment 4. A 2026 multi-institutional cohort study found that while SSRIs showed the highest hyponatremia risk (HR 1.18), the "other" antidepressant category (which includes trazodone) showed no significant increased risk compared to other antidepressants (HR 0.90) 5. However, this doesn't negate the FDA's direct warning about trazodone's hyponatremia risk.
Critical Monitoring Protocol
For patients starting trazodone 100 mg for insomnia, particularly those ≥60 years old or on diuretics:
- Measure baseline serum sodium before initiating therapy
- Monitor serum sodium within the first 2-4 weeks of treatment when risk is highest 4
- If unexplained symptoms develop (confusion, headache, weakness, falls), immediately check sodium levels 1
- In symptomatic hyponatremia, discontinue trazodone immediately and institute appropriate medical intervention 1
Additional Safety Concerns for Insomnia Use
Beyond hyponatremia, trazodone for insomnia carries other significant risks. A 2025 study in hypertensive older adults found trazodone users had a 58.3% incidence of syncope and falls versus 21.2% in non-users, along with greater orthostatic blood pressure drops 6. The 2016 American College of Physicians guideline notes that trazodone lacks FDA approval specifically for insomnia and evidence supporting its use is limited 7. A 2023 clinical appraisal concluded that the majority of expert panelists agreed trazodone should not be first-line therapy for insomnia due to limited published evidence 8.
Bottom line: Hyponatremia is a real, FDA-documented risk with trazodone that requires proactive sodium monitoring, especially in elderly patients and during the initial weeks of therapy.